Doug Solomon
Managing Director in the Global Healthcare Investment Banking Group
Barclays Capital

Doug Solomon is a Managing Director in the Global Healthcare Investment Banking Group at Barclays Capital (formerly Lehman Brothers).  Doug joined Barclays Capital in 1999.  Currently, Doug manages and originates Barclays’ medical technology business, and historically, executed mergers and acquisitions across the healthcare spectrum, including life sciences.  During Doug’s ten years of banking experience, he has led the execution of numerous capital raisings and M&A transactions totaling over $70 billion.  Doug holds an MBA in finance from Columbia Business School.

Selected transactions:

Client

Transaction
Datascope
  • $865 million sale to Getinge AB
  • $240 million sale of Patient Monitoring to Mindray
Serenex
  • Sale to Pfizer (value not disclosed)
Aspreva
  • $940 million sale to Galenica
Adnexus Therapeutics
  • $505 million sale to Bristol Myers Squibb
Ilypsa
  • $420 million sale to Amgen
Morphotek
  • $350 million sale to Eisai
Domantis
  • $450 million sale to GlaxoSmithKline
PowderMed
  • Sale to Pfizer (value not disclosed)
Avidia
  • $450 million sale to Amgen
Rinat Neuroscience
  • Sale to Pfizer (value not disclosed)
Idun
  • $298 million sale to Pfizer
Syrrx
  • $270 million sale to Takeda
Esperion Therapeutics
  • $1.3 billion sale to Pfizer
RTI Biologics
  • $500 million merger with Tutogen
Dako A/S
  • $1.3 billion sale to EQT